scholarly journals Predicting sustained ventricular arrhythmias in dilated cardiomyopathy: a meta‐analysis and systematic review

2020 ◽  
Vol 7 (4) ◽  
pp. 1430-1441 ◽  
Author(s):  
Arjan Sammani ◽  
Elham Kayvanpour ◽  
Laurens P. Bosman ◽  
Farbod Sedaghat‐Hamedani ◽  
Tanja Proctor ◽  
...  
Keyword(s):  
Systematic Review ◽  
Dilated Cardiomyopathy ◽  
Ventricular Arrhythmias ◽  
Meta Analysis

scholarly journals Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta‐analysis

2021 ◽  
Author(s):  
Gabriela M. Prado ◽  
Felix Mahfoud ◽  
Renato D. Lopes ◽  
Dalmo A. R. Moreira ◽  
Rodolfo Staico ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ventricular Arrhythmias ◽  
Renal Denervation ◽  
Meta Analysis

scholarly journals VENTRICULAR ARRHYTHMIAS WITH IBRUTINIB USE A SYSTEMATIC REVIEW AND META ANALYSIS

2021 ◽  
Vol 77 (18) ◽  
pp. 3333
Author(s):  
Yaser Khalid ◽  
Neethi Dasu ◽  
Kirti Dasu ◽  
Michael Fradley ◽  
Ankit Shah
Keyword(s):  
Systematic Review ◽  
Ventricular Arrhythmias ◽  
Meta Analysis

P5976Prediction of ventricular arrhythmias with mechanical dispersion assessed by strain echocardiography: a systematic review and meta-analysis

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
H Kawakami ◽  
N Nerlekar ◽  
K H Haugaa ◽  
T Edvardsen ◽  
T H Marwick
Keyword(s):  
Systematic Review ◽  
Risk Stratification ◽  
Predictive Value ◽  
Ventricular Arrhythmias ◽  
Speckle Tracking ◽  
Meta Analysis ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Weighted Mean ◽  
Mechanical Dispersion

Abstract Background Recent studies have demonstrated that left ventricular mechanical dispersion (LVMD) assessed by speckle tracking might be a powerful marker in risk stratification for ventricular arrhythmias (VA). We sought to perform a systematic review and meta-analysis to i) assess the prognostic value of this parameter (previous studies were predominantly single-center), ii) define the value relative to other parameters, iii) identify the most appropriate cutoff for designating risk. Purpose To assess the association between LVMD and the incidence of VA. Methods A systemic review of studies reporting the predictive value of LVMD for VA was undertaken from a search of Medline and Embase. LVMD was defined as the standard deviation of time from Q/R on ECG to peak negative strain from each LV segment. VA events were defined as sudden cardiac death, cardiac arrest, documented ventricular tachyarrhythmia, and appropriate implantable cardioverter defibrillator therapy. Hazard ratios (HRs) were extracted from univariable and multivariable models reporting on the association of LVMD and VA and described as pooled estimates with 95% confidence intervals (CIs). In a meta-analysis, the predictive value of LVMD was compared to that of left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS). Results Among 3198 patients (weighted mean, 63 years, 30% female; 82% ischemic heart disease) in 12 published articles, 387 (12%) had VA events over a follow-up (17–70 months). Patients with VA events had a significantly greater mechanical dispersion compared with those without VA events (weighted mean difference, −20.3 ms; 95% CI, −27.3 to −13.2; p<0.01); 60 ms was found to be the optimal cutoff LVMD value for predicting VA events. Each 10 ms increment of LVMD was significantly and independently associated with VA events (HR, 1.19; 95% CI, 1.09 to 1.29; p<0.01). The predictive value of LVMD was superior to that of LVEF or GLS (Figure). Figure 1 Conclusion LVMD assessed by speckle tracking provides important predictive value for VA in patients with a number of cardiac diseases and appears to have superior predictive value to LVEF and GLS for risk stratification.

scholarly journals Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review

2022 ◽  
Vol 7 ◽  
pp. 9
Author(s):  
Kathryn A. McGurk ◽  
Melpomeni Kasapi ◽  
James S. Ware
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Dilated Cardiomyopathy ◽  
Association Studies ◽  
Meta Analysis ◽  
The United States ◽  
Human Consumption ◽  
Cochrane Central Register ◽  
Genome Wide Association Studies ◽  
Taurine Supplementation

Background: Taurine, 2-aminoethanesulfonic acid, is an amino acid found in animal products. Taurine is produced for human consumption as a supplement and ingredient in beverages. Supplementation is a safe, inexpensive, and effective treatment for dilated cardiomyopathy (DCM) in domestic mammals, however it is currently unlicensed in Europe and the United States for human medical treatment. Recent genome-wide association studies of DCM have identified the locus of the taurine transporter (SLC6A6). To assess whether taurine supplementation may be a novel therapeutic option for DCM, we undertook a systematic review. Methods: Four electronic databases (PubMed, Cochrane Central Register, Web of Science, Biomed Central) were searched until 11/03/21. Included studies of human participants reported measured phenotypes or symptoms for cardiomyopathy, heart failure (HF), or altered left ventricle structure or function, administering taurine in any formulation, by any method. Non-English articles were excluded. Meta-analysis was completed in R software (version 3.6.0). The Newcastle-Ottawa Scale quality assessment score (NOQAS) tool was used to assess bias. Results: 285 articles were identified, of which eleven met our criteria for inclusion. Only one paper was deemed “high quality” using the NOQAS tool. Taurine supplementation varied across studies; by dose (500 mg to 6g per day), frequency (once to thrice daily), delivery method (tablet, capsule, drink, powder), and duration (2 to 48 weeks). Patient inclusion was all-cause HF patients with ejection fraction (EF) <50% and no study was specific to DCM. While improvements in diastolic and systolic function, exercise capacity, and haemodynamic parameters were described, only EF and stroke volume were measured in enough studies to complete a meta-analysis; the association was not significant with all-cause HF (P<0.05). No significant safety concerns were reported. Conclusions: A formal clinical trial is needed to address whether taurine supplementation is beneficial to the approximately 1/250 individuals with DCM in the population.

Sign in / Sign up

Export Citation Format

Share Document